

## **BAISHIDENG PUBLISHING GROUP INC**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## **ESPS PEER-REVIEW REPORT**

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 28668

Title: The effect of Clostridium perfringens enterotoxin on gastric cancer cells SGC7901

which highly expressed Claudin-4 protein

Reviewer's code: 03647317

Reviewer's country: United States

Science editor: Jing Yu

**Date sent for review:** 2016-07-21 18:41

Date reviewed: 2016-09-05 10:51

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[ Y] Grade B: Minor language	[ ] The same title	[ ] High priority for
[ Y] Grade C: Good	polishing	[ ] Duplicate publication	publication
[ ] Grade D: Fair	[ ] Grade C: A great deal of	[ ] Plagiarism	[ ] Rejection
[ ] Grade E: Poor	language polishing	[Y]No	[ ] Minor revision
	[ ] Grade D: Rejected	BPG Search:	[ Y] Major revision
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[ Y ] No	

## **COMMENTS TO AUTHORS**

It was my pleasure to review the manuscript from Liang and his colleagues. This is an interesting article reporting the therapeutic effect of clostridium perfringens enterotoxin (CPE) on gastric cancer cells (SGC7901 cells) and on a subcutaneous tumor in nude mice model. I found a topic is interesting but have several points to address and improve the manuscript as below. 1. In the results section, CPE cytotoxicity in SGC7901 cells, authors stated that after treated for 24 hours with CPE (0-10 mg/L), "significant dose-dependent" cytolysis was obviously detected in SGC7901 cells by MTT assay (Fig 2B). To my eyes, the bar of CPE 4, 6, 8, may not significantly different. Please explain how you define dose dependent and which group that you compare in this figure? Do you compare with only the group prior (ie. Group 8 and 6) or you compare with all groups and found that it is significantly different which suggested dose-dependent? 2. What is the implication for this research? Authors should address clinical implication of this study. Can you provide me previous clinical data or trial that using CPE in the treatment of cancer or disease in human? Also, in CPE (+) group, injection site skin necrosis, and enteritis were also observed in 3/7 mice (43%) which are high. In the



## **BAISHIDENG PUBLISHING GROUP INC**

8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

concept of cancer treatment, quality of life is one of the most important factors. The author should put this in the limitation of CPE and further studies are needed in the clinical implication of CPE in gastric cancer.